MedTrace Logo

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

NCT00719212 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2016-01-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma failing frontline chemotherapy.

Conditions

  • Ovarian Neoplasms

Interventions

BIOLOGICAL

AMG 479

Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle

Sponsors & Collaborators

  • Translational Research in Oncology

    lead OTHER

Principal Investigators

  • Gottfried E Konecny, MD · University of California, Los Angeles

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States
  • Canada
  • France
  • Germany
  • Ireland
  • Israel
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00719212 on ClinicalTrials.gov